Agilent alleges that Twist CEO Emily Leproust and other employees stole trade secrets from it. A trial date has been set for Feb. 24, 2020.
GenAhead said it will use the IP it had licensed from ERS for genome editing applications in pharmaceutical drug discovery and development.
Under the terms of the agreements, Thermo Fisher obtains global non-exclusive rights to products, tools, and research services involving the technologies.
PGDx has the exclusive rights to develop both tissue- and blood-based diagnostics using MSK’s TMB-related intellectual property.
Premaitha had been sued by Illumina for allegedly infringing on five patents related to noninvasive prenatal testing with its Iona test.
Cornell claims that it was fraudulently induced into settling a patent-infringement lawsuit it filed with Life Tech against Illumina.
The Broad Institute also announced announced a setback in proceedings over a CRISPR patent application filed in Europe.
Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test.
The collaborators will grant the licenses to any entities wanting to use the technology for commercial agricultural research and product development.
The nonexclusive license allows Arcadia to use the patented technology to develop nutritional and agricultural productivity traits in its core crops.
Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.
The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.
ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.
In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.